Blue Light Cystoscopy with Cysview utilizes a special scope and dye to detect and treat non muscle invasive bladder cancer.

In the 10-Q report, CG Oncology reported a net loss of $34.5 million for the three months ended March 31, 2025, compared to a ...

Immune checkpoint inhibitors have shown a survival benefit in patients with metastatic urothelial cancer, so investigators trialed neoadjuvant nivolumab and ipilimumab in patients with muscle-invasive ...

Welcome to the Relmada Therapeutics first-quarter 2025 earnings call. (Operator Instructions) As a reminder, this conference is being recorded, and will be available for replay on the location website ...

Q1 2025 Earnings Call Transcript May 12, 2025 Relmada Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0 ...

Q1 2025 Earnings Call Transcript May 12, 2025 UroGen Pharma Ltd. misses on earnings expectations. Reported EPS is $-0.92 EPS, ...

The approval in MIBC was based on positive results from the phase 3 NIAGARA trial, in which the Imfinzi regimen demonstrated ...

Positive initial Phase 2 proof-of-concept data for NDV-01 at AUA 2025 showing a 90% overall response rate at any time in non-muscle invasive bladder cancer (US prevalence 600K patients) The Phase 2 st ...

Detailed price information for Artara Therapeutics Inc (TARA-Q) from The Globe and Mail including charting and trades.

High-risk NMIBC is characterised by poor prognosis, with half of patients recurring despite effective treatment with the ...

The antibody has been approved for muscle-invasive bladder cancer (MIBC) in the US and other nations, based on the outcomes ...

Colin P.N. Dinney, MD, provides some background on translational analyses from the BOND-003 and CORE-001 trials.